Clinuvel Pharmaceuticals Ltd
ASX:CUV
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.91
18.09
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd
Total Liabilities & Equity
Clinuvel Pharmaceuticals Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Liabilities & Equity
AU$231.1m
|
CAGR 3-Years
29%
|
CAGR 5-Years
30%
|
CAGR 10-Years
30%
|
|
|
Immutep Ltd
ASX:IMM
|
Total Liabilities & Equity
AU$201.6m
|
CAGR 3-Years
35%
|
CAGR 5-Years
38%
|
CAGR 10-Years
23%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities & Equity
$669.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities & Equity
$38B
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
20%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities & Equity
AU$406m
|
CAGR 3-Years
37%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities & Equity
AU$91.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
69%
|
CAGR 10-Years
35%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
231.1m
AUD
Based on the financial report for Jun 30, 2024, Clinuvel Pharmaceuticals Ltd's Total Liabilities & Equity amounts to 231.1m AUD.
What is Clinuvel Pharmaceuticals Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
30%
Over the last year, the Total Liabilities & Equity growth was 19%. The average annual Total Liabilities & Equity growth rates for Clinuvel Pharmaceuticals Ltd have been 29% over the past three years , 30% over the past five years , and 30% over the past ten years .
You don't have any saved screeners yet
